Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Thymosin Alpha-1: Research Applications Comparison

Choosing thymosin alpha-1 for cancer adjunct research requires aligning peptide specifications with study design. Different applications demand different purity thresholds, sequencing verification levels, and storage formats. Dendritic cell maturation assays (

This comparison does not assign a generated winner or score.

  • Choosing thymosin alpha-1 for cancer adjunct research requires aligning peptide specifications with study design. Different applications demand different purity thresholds, sequencing verification levels, and storage formats.
  • Dendritic cell maturation assays (in vitro)
  • ≥95% by HPLC
  • Mass spec confirmation (3,108 Da)
  • 10–100 μg/mL culture media
  • Lyophilised, single-use aliquots
  • Lower purity acceptable for screening; sequencing not critical if mass is confirmed
  • T-cell proliferation assays (in vitro)
  • ≥98% by HPLC
  • N-terminal sequencing (10 residues)
  • 1–10 μg/mL culture media
  • Lyophilised, reconstitute fresh per experiment
  • Sequence verification required. Deletion peptides produce false negatives
  • Tumor microenvironment studies (in vivo, mouse models)
  • Full sequencing (28 residues) or MS/MS
  • 100–200 μg per injection, twice weekly
  • Lyophilised, sterile-filtered post-reconstitution
  • Full sequencing mandatory for publication; endotoxin testing required (<1 EU/mg)
  • Checkpoint inhibitor combination trials (preclinical)
  • ≥99% by HPLC
  • Full sequencing + endotoxin testing
  • 1.6 mg human equivalent dose
  • Lyophilised, GMP-grade synthesis preferred
  • Highest purity required; regulatory-grade CoA needed for IND submissions
  • Post-chemotherapy immune recovery models
  • 100–200 μg per injection
  • Lyophilised, stored at −20°C until use
  • Sequencing verifies immune-active region; batch consistency critical across multi-week studies
  • Cytokine secretion profiling (multiplex assays)
  • Mass spec + sequencing
  • 0.1–10 μg/mL
  • Lyophilised, single-use vials
  • Off-target cytokine activation from impurities confounds results. High purity non-negotiable
More references

Related material